Completed PHASE4 INTERVENTIONAL 3-arm NCT03363035

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (H-REPLACE)

Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial

Sponsor: Second Xiangya Hospital of Central South University

Conditions Acute Coronary Syndrome Myocardial Infarction Myocardial Ischemia Unstable Angina

Interventions Enoxaparin Rivaroxaban 2.5 mg Rivaroxaban 5 mg

Updated 13 times since 2017 Last updated: Feb 21, 2022 Started: Jan 15, 2018 Primary completion: Nov 11, 2021 Completion: Nov 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03363035, this PHASE4 trial focuses on Acute Coronary Syndrome and Myocardial Infarction and remains completed. Sponsored by Second Xiangya Hospital of Central South University, it has been updated 13 times since 2018, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Mar 2022 — Jul 2024 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Nov 2021 — Mar 2022 [monthly]

Active Not Recruiting PHASE4
Jan 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE4

▶ Show 8 earlier versions

Dec 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Apr 2020 — Dec 2020 [monthly]

Recruiting PHASE4
Apr 2019 — Apr 2020 [monthly]

Recruiting PHASE4
Jan 2019 — Apr 2019 [monthly]

Recruiting PHASE4
Aug 2018 — Jan 2019 [monthly]

Recruiting PHASE4
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE4
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Feb 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Xiangya Hospital of Central South University

Data source: Second Xiangya Hospital of Central South University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changde, China , Changsha, China , Chenzhou, China , Hengyang, China , Huaihua, China , Jishou, China , Loudi, China , Shaoyang, China , Xiangtan, China , Xianxiang, China and 4 more locations